The prognostic value of apoptotic and proliferative markers in breast cancer

Breast Cancer Research and Treatment

Volumn 142, Issue 2, 2013, Pages 323-339

  Engels, Charla C ^a   Ruberta, Francesca ^a   De Kruijf, Esther M ^a   Van Pelt, Gabi W ^a   Smit, Vincent T H B M ^a   Liefers, Gerrit Jan ^a   Matsushima, Tomoko ^b   Shibayama, Masaki ^b   Ishihara, Hideki ^b   Van De Velde, Cornelis J H ^a   Kuppen, Peter J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SYSMEX CORPORATION   (Japan)

Author keywords

Apoptosis; Breast cancer; Proliferation; Subtypes

Indexed keywords

BIOLOGICAL MARKER; CASPASE 3; KI 67 ANTIGEN; PROTEIN P53;

ACCURACY; ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CLASSIFICATION; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; VERY ELDERLY;

ADULT; AGED; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CELL PROLIFERATION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84890433690     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2748-y     Document Type: Article

References (18)

1. Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17:R245-R262
2. O'Donovan N, Crown J, Stunell H et al (2003) Caspase 3 in breast cancer. Clin Cancer Res 9:738-742
3. Pathmanathan N, Balleine RL (2013) Ki67 and proliferation in breast cancer. J Clin Pathol 66(6):512-516
4. Gong P, Wang Y, Liu G, Zhang J, Wang Z (2013) New insight into Ki67 expression at the invasive front in breast cancer. PLoS ONE 8:e54912
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235
6. van Nes JG, de Kruijf EM, Faratian D et al (2011) COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125:671-685
7. de Kruijf EM, van Nes JG, Sajet A et al (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272-1280
8. Nout RA, Bosse T, Creutzberg CL et al (2012) Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation. Gynecol Oncol 126:466-473
9. Kim SJ, Nakayama S, Shimazu K et al (2012) Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers. Ann Oncol 23:891-897
10. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
11. Nyiraneza C, Jouret-Mourin A, Kartheuser A et al (2011) Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer. Hum Pathol 42:1897-1910
12. van Nes JG, Smit VT, Putter H et al (2009) Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients. Br J Cancer 100:494-500
13. Jager JJ, Jansen RL, Arends JW (2002) Clinical relevance of apoptotic markers in breast cancer not yet clear. Apoptosis 7:361-365
14. Oh YL, Choi JS, Song SY et al (2001) Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 51:94-99
15. Ross JS, Linette GP, Stec J et al (2003) Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 3:573-585
16. Parton M, Krajewski S, Smith I et al (2002) Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 8:2100-2108
17. Zeestraten EC, Maak M, Shibayama M et al (2012) Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer 106:133-140
18. Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302:1685-1692